share_log

Orsini Now Distributing CASGEVY (Exagamglogene Autotemcel), a Gene-Editing Therapy

Orsini Now Distributing CASGEVY (Exagamglogene Autotemcel), a Gene-Editing Therapy

奧爾西尼現在正在分發CASGEVY(Exagamglogene Autotemcel),一種基因編輯療法
PR Newswire ·  11/14 21:00

ELK GROVE VILLAGE, Ill., Nov. 14, 2024 /PRNewswire/ -- Orsini has been chosen by Vertex Pharmaceuticals Incorporated to dispense gene-editing therapy CASGEVY (exagamglogene autotemcel). CASGEVY is a CRISPR/Cas9 gene-edited cell therapy indicated for the treatment of patients aged 12 years and older with (1) sickle cell disease (SCD) with recurrent vaso-occlusive crises or (2) transfusion-dependent β-thalassemia (TDT). Read the Full Prescribing Information here.

愛文思控股已被福泰製藥公司選中分發基因編輯療法CASGEVY(exagamglogene autotemcel)。CASGEVY是一種CRISPR/Cas9基因編輯細胞療法,適用於12歲及以上患有(1)具有反覆血管梗阻性危機的鐮狀細胞病(SCD)或(2)依賴輸血的β-地中海貧血(TDT)患者。請在此處閱讀完整的處方信息。

"With our Cell and Gene Therapy Center of Excellence established over seven years ago, Orsini is well-positioned to partner with Vertex to distribute CASGEVY," Brandon Tom, Orsini's CEO, said.

「鑑於我們設立的細胞和基因療法卓越中心已有七年多,Orsini很有能力與福泰製藥合作分發CASGEVY,」Orsini的首席執行官Brandon Tom說。

About Orsini

關於奧爾西尼

Providing patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary treatments for rare diseases. Through integrated rare disease pharmacy solutions including pharmacy distribution, patient services, clinical management and convenient home infusion services, Orsini simplifies how patients connect to advanced therapies. Orsini's high-touch care model centers on experienced and trained therapy care teams that provide personalized patient care to ensure that No Patient is Left Behind.

自1987年以來,Orsini一直爲患者提供全面和富有同情心的護理,是罕見疾病和基因療法領域的領導者。Orsini與生物製藥創新者、醫療保健提供者和償付方合作,支持患者及其家人獲得罕見疾病的革命性治療方案。通過集成的罕見疾病藥學解決方案,包括藥房分銷、患者服務、臨床管理和方便的家庭輸液服務,Orsini簡化了患者接觸先進療法的方式。Orsini的高接觸護理模式以經驗豐富和訓練有素的治療護理團隊爲中心,爲患者提供個性化的護理,確保沒有患者被落下。

Orsini Specialty Pharmacy holds accreditations with the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC and NABP. Orsini has earned URAC's Rare Disease Pharmacy Center of Excellence Designation and ACHC's Distinction in Rare Diseases and Orphan Drugs. For more information, contact Orsini at 847-734-7373 ext. 505, email us at [email protected], or visit .

Orsini專科藥房獲得了衛生保健認證委員會(ACHC)、聯合委員會、URAC和NABP的認證。 Orsini榮獲了URAC的罕見病藥房卓越中心認定和ACHC的罕見病和孤兒藥品區別。 欲獲得更多信息,請聯繫Orsini,電話847-734-7373轉505,電子郵件聯繫[email protected],或訪問網站。

SOURCE Orsini

來源:Orsini

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎?

440k+
440k+

Newsrooms &
新聞發佈室&

Influencers
影響力人士
9k+
9k+

Digital Media
數字媒體

Outlets
Outlets
270k+
270k+

Journalists
記者

Opted In
Opted In
GET STARTED
開始使用

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論